APA (7th ed.) Citation

IW, C., CW, L., PT, L., W, T., CW, S., TH, W., . . . CY, L. (2026). Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab. Cancer immunology, immunotherapy : CII, 75(2), 59. https://doi.org/10.1007/s00262-026-04308-z

Chicago Style (17th ed.) Citation

IW, Chen, et al. "Non-thyroidal Illness Syndrome Predicts Poor Prognosis in Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab." Cancer Immunology, Immunotherapy : CII 75, no. 2 (2026): 59. https://doi.org/10.1007/s00262-026-04308-z.

MLA (9th ed.) Citation

IW, Chen, et al. "Non-thyroidal Illness Syndrome Predicts Poor Prognosis in Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab." Cancer Immunology, Immunotherapy : CII, vol. 75, no. 2, 2026, p. 59, https://doi.org/10.1007/s00262-026-04308-z.